Abstract
Background Advances in mass spectrometry are providing new insights into the role of metabolomics in the aetiology of many diseases. Studies in retinopathy of prematurity (ROP), for instance, overlooked the role of metabolic alterations in disease development. Here, we employed comprehensive metabolic profiling and gold-standard metabolic analysis to explore major metabolites and metabolic pathways significantly affected in early stages of pathogenesis toward ROP.
Methods This is a multicentre, retrospective case-control study. We collected serums from 57 ROP cases and 57 strictly baseline matched non-ROP controls. Non-targeted ultrahigh performance liquid chromatography-tandem mass spectroscopy (UPLC-MS/MS) from Metabolon, Inc. was used to detect the metabolites in serum samples. Machine learning was used to unravel most affected metabolites and pathways in ROP development.
Results Compared to non-ROP controls, we found a significant metabolic perturbation in the ROP serums, featured with an increase in lipid, nucleotide, carbohydrate metabolites and a lower level of peptides. Machine leaning helped to distinguish a cluster of metabolic pathways (glycometabolism, redox homeostasis, lipid metabolism and arginine pathway) that were strongly related to the development of ROP. In addition, we found that the severity of ROP was related to the level of creatinine and ribitol.
Conclusion In the current study, our results suggested a strong link between metabolic profiling and retinal neovascularization during ROP pathogenesis. These findings provided an insight into identifying novel metabolic biomarkers for ROP diagnosis and prevention.
Competing Interest Statement
The authors have declared no competing interest.
Clinical Trial
ChiCTR1900020677
Funding Statement
The research was supported by Shenzhen Science and Technology Innovation Commission basic discipline layout project, China (JCYJ20170817112542555) and Medical and health projects of Sanming.
Author Declarations
I confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.
Yes
The details of the IRB/oversight body that provided approval or exemption for the research described are given below:
Ethics Committee of Affiliated Shenzhen Eye Hospital of Jinan University
All necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived.
Yes
I understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).
Yes
I have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.
Yes
Footnotes
Sources of funding: The research was supported by Shenzhen Science and Technology Innovation Commission basic discipline layout project, China (JCYJ20170817112542555) and Medical and health projects of Sanming.
Conflict of interest statement: The authors have declared that no conflict of interest exists.
Data Availability
All data that support the findings of this study are available within the article and Mendeley dataset. The Supplementary Information, Python code and Metabolomic Data are available in https://dx.doi.org/10.17632/7r7xt6pf6x, Doi: 10.17632/7r7xt6pf6x. Its Demographic Data File are available from the corresponding author upon reasonable request.
